Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA Drug Information Soundcast in Clinical Oncology (DISCO) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Latest Drug Information Soundcasts

Title	Date	Link to Podcast	Link to Transcript
FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur In our inaugural podcast, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series.	May 16, 2017	Run Time: 00:3:19	Transcript
FDA D.I.S.C.O.: Rucaparib in Ovarian CancerFDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies.	May 17, 2017	Run Time: 00:5:13	Transcript
FDA D.I.S.C.O.: Niraparib in Ovarian CancerFDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.	May 18, 2017	Run Time: 00:5:56	Transcript
FDA D.I.S.C.O.: Avelumab in Merkel Cell CarcinomaFDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.	May 22, 2017	Run Time: 00:6:28	Transcript
FDA D.I.S.C.O.: First Tissue/Site Agnostic ApprovalThe D.I.S.C.O. hosts discuss the agency’s first approval of a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.	May 30, 2017	Run Time: 00:6:00	Transcript
FDA D.I.S.C.O.: Two approvals for ALK-positive non-small cell lung cancer FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.	July 25, 2017	Run Time: 00:9:00	Transcript
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung CancerFDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.	July 28, 2017	Run Time: 00:6:00	Transcript
FDA D.I.S.C.O.: L-glutamine for sickle cell diseaseFDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease.	August 17, 2017	Run Time: 00:5:29	Transcript
FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemia FDA medical oncologists discuss the Aug. 3, 2017, approval of Vyxeos for treatment of acute myelogenous leukemia.	September 15, 2017	Run Time: 00:4:59	Transcript
FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer.	December 21, 2017	Run Time: 00:8:29	Transcript
FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy FDA medical oncologists discuss the first approval of a chimeric antigen receptor (CAR) T-cell immunotherapy.	February 23, 2018	Run Time: 00:5:59	Transcript
FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma FDA medical oncologists discuss the December 20, 2017, approval of nivolumab for the adjuvant treatment of patients with melanoma.	February 26, 2018	Run Time: 00:5:00	Transcript